Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retreatment of Recurrent Contractures in Joints Effectively Treated With AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX/XIAPEX]) in an Auxilium-sponsored Phase 3 Study in the United States, Australia, and Europe

Trial Profile

Retreatment of Recurrent Contractures in Joints Effectively Treated With AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX/XIAPEX]) in an Auxilium-sponsored Phase 3 Study in the United States, Australia, and Europe

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Dupuytren's contracture
  • Focus Therapeutic Use
  • Acronyms AA4500 Re-treatment Study
  • Sponsors Auxilium Pharmaceuticals; Endotis Pharma
  • Most Recent Events

    • 15 May 2015 Results published in the Endo Pharmaceuticals media release.
    • 16 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Jan 2014 Planned number of patients changed from 100 to 150 as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top